Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amgen, Novartis Report Positive Data for Migraine Drug

By Ryan Bushey | November 17, 2016

Amgen and Novartis are one step closer to having a contender in the migraine treatment space.

Both companies reported on Wednesday that patients diagnosed with episodic migraines taking their investigational therapy, erenumab, reported fewer debilitating headaches per month compared to the participants taking placebo, according to Endpoints News.

Investigators running this second randomized late-stage study recruited 955 patients for this test who on average experienced 8.3 migraine days each month. Patients were administered either 70mg or 140mg of the drug once a month for a six month period.  

Both dosing regimens elicited statistically significant results. The 70mg and 140mg treatment of erenumab lowered the average number of migraine days suffered by these groups down to 3.2 and 3.7 days respectively while the placebo recipients only experienced 1.8 day reduction.

These results in conjunction with previous tests evaluating the drug’s impact on chronic migraine sufferers will help these pharmaceutical companies make their case for regulatory approval.

Other companies like Allergan and Eli Lilly are developing their own migraine treatments as well.

However, Amgen and Novartis are hoping to distinguish themselves in this market because their candidate blocks the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to play a role in causing migraines. Rival therapies only focus on the ligand.

Analysts predict this drug could have blockbuster potential pulling in $1.3 billion in sales by 2023, explained Endpoints News.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE